1 study on Cdkn1a mechanism curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
**Tumors that express functional `p21/waf1` may be selectively vulnerable to GHRH antagonist therapy** — and conversely, cancers with silenced or mutated `p21` are likely non-responders. This mechanistic clarity could…